Sergio A. Giralt, MD, FACP
Professor of Medicine
Weill Cornell Medical College
Chief Attending Physician
Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
New York, New York
Dr. Sergio Giralt received his medical degree from Universidad Central de Venezuela. He completed his residency at Good Samaritan Hospital and his fellowship at The University of Texas MD Anderson Cancer Center. Dr. Giralt is Professor of Medicine at Weill Cornell Medical College and the Chief Attending Physician of the Adult Bone Marrow Transplant Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York City. In addition, he is the Melvin Berlin Family Chair in Myeloma Research.
Dr. Giralt is board certified in internal medicine with subspecialties in medical oncology and hematology. He is an active member of the American Medical Association, American College of Physicians, American Society of Hematology, American Society of Clinical Oncology, North American Society of Blood and Bone Marrow Transplantation (ASBMT), International Society of Hematotherapy and Graft Engineering, International Society of Haematology, and the Gerontological Society of America. Dr. Giralt previously served as chairperson on the executive board of the Center for International Blood and Marrow Transplant Research, the steering committee of the Blood and Marrow Transplant Clinical Trials Network, and is past president of ASBMT.
Dr. Giralt’s clinical and research activities include stem cell transplantation for patients with blood disorders and improving treatments for older patients who have acute and chronic leukemia. He has published and presented extensively on these topics. Additionally, Dr. Giralt has served as the principal investigator for a number of clinical trials that examine new treatment approaches for multiple myeloma and other blood cancers that aim to reduce symptom burden and improve treatment tolerability.
Dr. Sergio Giralt has received consultant fees and honoraria related to speakers’ bureau activities from Celgene Corporation, Genzyme Corporation, and Millennium Pharmaceuticals, Inc.